NCT01867294 - Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 9, 2014

Study Completion Date

June 13, 2014

Conditions

Advanced Malignant NeoplasmDermatologic Complication

Interventions

DRUG

Doxycycline

Given PO

PROCEDURE

Management of Therapy Complications

Moisturizer given topically

OTHER

Placebo

Given topically

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Spironolactone

Given topically

DRUG

Sunscreen

Given topically

DRUG

Therapeutic Hydrocortisone

Given topically

Trial Locations (5)

50309

Iowa-Wide Oncology Research Coalition NCORP, Des Moines

54449

Marshfield Clinic, Marshfield

56303

Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud

61801

Carle Cancer Center, Urbana

67214

Cancer Center of Kansas - Wichita, Wichita

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER